Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Mar 2022	51	Global Markets Direct	ASDR-599085

Published: Mar 2022 - Pages : 51 - Publisher : Global Markets Direct - Report code : ASDR-599085

Amgen Inc
Cinkate Corp
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Novadiol Inc
OPKO Health Inc
Scohia Pharma Inc
Shaanxi Micot Technology Co Ltd
TaiRx Inc
Vidasym Inc

Secondary Hyperparathyroidism Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

This report can be of interest as well:

Secondary Hyperparathyroidism Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-20...

Published: February, 2024 | Report code: ASDR-657591